To print: Select File and then Print from your browser's menu

Title: FDA Approves New Oral Contraceptive Loestrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets)

"FDA Approves New Oral Contraceptive Loestrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets)"

First Birth Control Pill to Provide 24 Days of Active Hormonal Therapy ROCKAWAY, NJ -- February 20, 2006 -- Warner Chilcott announced that the U.S. Food and Drug Administration (FDA) has approved its 24-day oral contraceptive, Loestrin(R) 24 Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), for the prevention of pregnancy. Loestrin 24 Fe ("Loestrin 24") is the first birth-control pill approved in the United States that provides 24 days of active hormonal therapy and four days of iron containing placebo pills. "This FDA approval is a significant step forward for Warner Chilcott as we continue to sharpen our therapeutic focus on women's health and expand our product portfolio in this area," said Roger Boissonneault, Chief Executive Officer of Warner Chilcott. SOURCE: Warner Chilcott

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.